Established drugs can be repurposed for new clinical indications for unmet medical needs when protected by strong intellectual property. Historical drug safety data and existing manufacturing ‘know-how’ can fast-track clinical development and reduce commercialisation costs for repurposed drugs.
Life is complex! For every diagnosis, there are multiple factors and biological interactions involved. We develop therapeutics targeting multiple pathways involved in injury or on the road to disease producing better outcomes for patients.
PENTOSAN POLYSULPHATE SODIUM (PPS)
We focus on PPS because this FDA approved drug has a long history of safety and efficacy in treating interstitial cystitis and deep vein thrombosis. Our patents cover new applications in bone marrow edema (BME) and respiratory disease.
Inflammation is a complex biological response to injury, infection or allergy, which has short and long term components mediated by factors produced by immune cells.
Paradigm Phase 2 Ross River Virus Clinical Trial Update
14 September 2017
Paradigm Biopharmaceuticals Ltd. is pleased to announce strong momentum with its Phase 2 Ross River virus clinical trial…
A paradigm shift in treating osteoarthritis pain
11 September 2017
Paradigm Biopharmaceuticals Ltd. (ASX:PAR) is pleased to announce the peer-reviewed publication of a patient case study…
Paradigm – First Ross River Trial Participant Treated
9 August 2017
Paradigm Biopharmaceuticals announces that it has successfully dosed its first patient in its Phase 2 Alphavirus clinical trial…
Alphaviruses, including Ross River virus (RRv) and Chikungunya (CHIKV) are mosquito-transmitted arthritogenic alphaviruses that cause epidemics of severe musculoskeletal disease.
*Simon, Fabrice et al. “Chikungunya Virus Infection.” Current Infectious Disease Reports 13.3 (2011): 218–228. PMC. Web. 10 Oct. 2016
OA is a condition with a significant unmet medical need. Opioid abuse resulting from mismanagement of pain is a major problem in the US and most western countries.
*National Institute of Health; Emerging drugs for osteoarthritis; Hunter DJ and Matthews G 16(3): 479–491; 2011 September
Bone Marrow Edema (BME)
Worldwide hip & knee surgical implant market is $16.7 billion, will be $33 billion by 2022. Acute joint injury leads to osteoarthritis.
Bone Marrow Edema (BME)
>50% top ranked skiers have injured knee ligaments (women 5x more susceptible than men)
CLINICAL TRIALS PIPELINE
RESEARCH & DEVELOPMENT
Paradigm is evaluating new intellectual property that has relevance to treating inflammation, especially in orthopaedics.